Biotia
PrivateLast Round
Series A
Extension
Oct 1, 2026
Total Funding Raised
$19.4M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Biotia operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A Extension round in October 2026.
Biotia is a health technology company that provides sequencing-based technology and proprietary AI-powered software to identify microorganisms and antimicrobial resistance.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Healthcare Analytics, Precision Medicine, Vertical SaaS
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biotia Comparables
Compare Biotia with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Noscendo GmbH | 84% | |
| Delve Bio | 84% | |
| Pathogenomix, Inc. | 82% |
For institutional investors. Book with your work email.
Biotia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 1, 2026 | ||||
| Grant | Jun 17, 2025 | ||||
| Series A | Aug 23, 2022 | ||||
| Seed | Dec 10, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biotia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Phoenix Venture Partners | Series A |
| Cloquet Capital Partners | Series A Extension |
| EGB Capital | Series A Extension |
| SeedtoB Capital | Series A |
| Convergent Ventures | Series A Extension |
| Tau Ventures | Seed, Series A |
| SK Square Americas | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2026
$9M raised from Cloquet Capital Partners and Convergent Ventures.
- Aug 22, 2026
Monthly visitors grew 123% MoM, reaching 5.6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- expands_facilitiesOct 2, 2026
Using $9M in new financing, Biotia plans to increase the capacity of its CLIA-certified laboratory in New York City.
- is_developingOct 2, 2026
Biotia plans to develop new diagnostic tests for women's health and orthopedic markets using capital raised on Oct 1st '26, while expanding its CLIA-certified laboratory in New York.
For institutional investors. Book with your work email.
Biotia Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biotia's valuation, stock price, and market status.
Is Biotia a public or private company?
Biotia is a private company.
What is the current stock price of Biotia?
Biotia is a private company, so its shares have no public market price. Caplight tracks Biotia's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biotia worth (valuation)?
Valuation information for Biotia is not publicly available.
Can I buy Biotia stock?
Biotia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biotia's last funding round?
Biotia's most recent funding round was Series A Extension on October 1, 2026.
Who are the main investors in Biotia?
Key investors in Biotia include OCA Ventures.
Will Biotia IPO soon?
No public IPO plans have been announced for Biotia.
How can I track Biotia secondary market activity?
Caplight tracks bids, offers, and trades in Biotia's shares on secondary markets.